Paradigm Changes in the Perioperative Setting for Non-small Cell Lung Cancer - Karen Reckamp, MD
Multimodal Management of Early-Stage NSCLC: EGFR-Targeted Therapy in Perioperative Settings
Current Management of Stage IIIA Non-Small Cell Lung Cancer: A Changing Paradigm (November 10, 2022)
Locally Advanced NSCLC: Operable Setting
Small Cell Lung Cancer Treatment - Dr. Jacob Sands, MD
Targeted therapy for early-stage lung cancer
The 2022 OncoAlert Colloquium DAY 3: Lung Cancer
AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach
Treatment & Management Of Lung Cancer Archives 2022 - 27 Jan
Immunotherapy as combination and neoadjuvant therapies in NSCLC
Expert report on neoadjuvant immune checkpoint inhibitors for NSCLC
Ramalingam Compares Third Generation EGFR TKI Osimertinib to Older Agents in NSCLC
Advances in Immunotherapy for Melanoma and Beyond
EGFR TKIs as Adjuvant Therapy in NSCLC
Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC
EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know
NADIM: baseline ctDNA as a prognostic factor for PFS
New Targets for Advanced Bladder Cancer
